

Cynthia A Lemere

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3824305/publications.pdf>

Version: 2024-02-01

65
papers

13,557
citations

109321

35
h-index

168389

53
g-index

79
all docs

79
docs citations

79
times ranked

16921
citing authors

#	ARTICLE	IF	CITATIONS
1	Microbiota in Neuroinflammation and Synaptic dysfunction: a focus on Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 19.	10.8	89
2	Acute Effects of Focused Ultrasound-Induced Blood-Brain Barrier Opening on Anti-Pyroglu3 Abeta Antibody Delivery and Immune Responses. <i>Biomolecules</i> , 2022, 12, 951.	4.0	9
3	Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 98.	6.2	152
4	<i>APOE</i> ϵ 4 Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome—Implications for Clinical Trials and Treatments for All. <i>JAMA Neurology</i> , 2021, 78, 913.	9.0	1
5	Focused ultrasound with anti-pGlu3 $A\beta$ enhances efficacy in Alzheimer's disease-like mice via recruitment of peripheral immune cells. <i>Journal of Controlled Release</i> , 2021, 336, 443-456.	9.9	21
6	Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain $A\beta$ Pathology in Transgenic Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11791.	4.1	10
7	Global C3 lowering alleviates hippocampal dysfunction and cognitive impairment in aged mice. <i>Alzheimer's and Dementia</i> , 2021, 17, e058736.	0.8	0
8	Long-Term Sex- and Genotype-Specific Effects of ^{56}Fe Irradiation on Wild-Type and APP ^{swe} /PS1 ^{dE9} Transgenic Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13305.	4.1	10
9	Focus Ultrasound-Induced Blood-Brain Barrier opening enhances anti-pGlu3 $A\beta$ mAb delivery and amyloid-beta plaque clearance. <i>Alzheimer's and Dementia</i> , 2021, 17, e058725.	0.8	0
10	Vaccination against the broadly expressed microbial antigen PNAG prevents cognitive decline in the APP-PS1 mouse model of Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e053793.	0.8	0
11	Global complement C3 lowering in adult mice protects hippocampal synaptic function.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e057867.	0.8	0
12	Microglia Do Not Take Up Soluble Amyloid-beta Peptides, But Partially Degrade Them by Secreting Insulin-degrading Enzyme. <i>Neuroscience</i> , 2020, 443, 30-43.	2.3	14
13	Phosphorylated $A\beta$ peptides in human Down syndrome brain and different Alzheimer's-like mouse models. <i>Acta Neuropathologica Communications</i> , 2020, 8, 118.	5.2	14
14	A novel inducible complement C3 conditional knockout mouse model: Generation and characterization. <i>Alzheimer's and Dementia</i> , 2020, 16, e047192.	0.8	0
15	Development of the clinical candidate PBD-C06, a humanized pGlu3- $A\beta$ -specific antibody against Alzheimer's disease with reduced complement activation. <i>Scientific Reports</i> , 2020, 10, 3294.	3.3	17
16	Effector function of anti-pyroglutamate-3 $A\beta$ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 12.	6.2	26
17	Space-like ^{56}Fe irradiation manifests mild, early sex-specific behavioral and neuropathological changes in wildtype and Alzheimer's-like transgenic mice. <i>Scientific Reports</i> , 2019, 9, 12118.	3.3	49
18	Active Amyloid- β Vaccination Results in Epigenetic Changes in the Hippocampus of an Alzheimer's Disease-Like Mouse Model. <i>Current Alzheimer Research</i> , 2019, 16, 861-870.	1.4	4

#	ARTICLE	IF	CITATIONS
19	BrightFocus Alzheimer™s Fast Track 2019. <i>Molecular Neurodegeneration</i> , 2019, 14, 48.	10.8	1
20	Age-related epigenetic changes in hippocampal subregions of four animal models of Alzheimer's disease. <i>Molecular and Cellular Neurosciences</i> , 2018, 86, 1-15.	2.2	31
21	P1-099: COMBINATION OF A GLUTAMINYL CYCLASE INHIBITOR (PQ912) AND A PYROGLUTAMATE- β SPECIFIC ANTIBODY (PBD-06) SHOWS ADDITIVE EFFECTS IN A MOUSE MODEL WITH ALZHEIMER'S DISEASE-LIKE PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P309.	0.8	0
22	Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research Society. <i>Molecular Syndromology</i> , 2018, 9, 279-286.	0.8	8
23	Traumatic Brain Injury in Aged Mice Induces Chronic Microglia Activation, Synapse Loss, and Complement-Dependent Memory Deficits. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3753.	4.1	98
24	Passive β Immunotherapy: Current Achievements and Future Perspectives. <i>Molecules</i> , 2018, 23, 1068.	3.8	41
25	Deposition of phosphorylated amyloid- β in brains of aged nonhuman primates and canines. <i>Brain Pathology</i> , 2018, 28, 427-430.	4.1	8
26	Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	401
27	The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. <i>Immunity</i> , 2017, 47, 566-581.e9.	14.3	1,741
28	[F4-06-02]: UPDATE OF THE AMYLOID HYPOTHESIS: COMPLEMENT MODULATES THE GLIAL RESPONSE TO β PLAQUES AND MEDIATES SYNAPSE LOSS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1218.	0.8	0
29	Immunotherapy targeting pyroglutamate-3 β : prospects and challenges. <i>Molecular Neurodegeneration</i> , 2016, 11, 48.	10.8	38
30	P3-108: Beneficial Effects of Anti-Inflammatory, RNS60, in Aged APPSWE/PS1DE9 Mice. , 2016, 12, P860-P860.		0
31	Complement and microglia mediate early synapse loss in Alzheimer mouse models. <i>Science</i> , 2016, 352, 712-716.	12.6	2,237
32	Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology. <i>Current Alzheimer Research</i> , 2015, 13, 18-29.	1.4	191
33	Down syndrome and Alzheimer's disease: Common pathways, common goals. <i>Alzheimer's and Dementia</i> , 2015, 11, 700-709.	0.8	218
34	The epigenetics of aging and neurodegeneration. <i>Progress in Neurobiology</i> , 2015, 131, 21-64.	5.7	334
35	Tau immunization: a cautionary tale?. <i>Neurobiology of Aging</i> , 2015, 36, 1316-1332.	3.1	28
36	Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. <i>Journal of Neuroscience</i> , 2015, 35, 13029-13042.	3.6	286

#	ARTICLE	IF	CITATIONS
37	An anti-pyroglutamate-3 A β vaccine reduces plaques and improves cognition in APP ^{swe} /PS1 ^{E9} mice. <i>Neurobiology of Aging</i> , 2015, 36, 3187-3199.	3.1	45
38	<i>In Vivo</i> Detection of Age- and Disease-Related Increases in Neuroinflammation by ¹⁸ F-GE180 TSPO MicroPET Imaging in Wild-Type and Alzheimer's Transgenic Mice. <i>Journal of Neuroscience</i> , 2015, 35, 15716-15730.	3.6	110
39	Anti-A β antibodies incapable of reducing cerebral A β oligomers fail to attenuate spatial reference memory deficits in J20 mice. <i>Neurobiology of Disease</i> , 2015, 82, 372-384.	4.4	37
40	P4-264: ARE ANTI-ABETA AGGREGATE-PREFERRING ANTIBODIES THE FUTURE FOR AD IMMUNOTHERAPY?. , 2014, 10, P881-P882.		2
41	S4-02-03: COMPLEMENT IN ALZHEIMER'S DISEASE: LESSONS FROM C3-DEFICIENT MICE. , 2014, 10, P240-P240.		0
42	Immunotherapy for Alzheimer's disease: hoops and hurdles. <i>Molecular Neurodegeneration</i> , 2013, 8, 36.	10.8	162
43	Pyroglutamate-3 Amyloid- β Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease-Like Transgenic Mouse Models. <i>American Journal of Pathology</i> , 2013, 183, 369-381.	3.8	102
44	F3-01-02: Alzheimer's disease and Down syndrome. , 2013, 9, P513-P513.		0
45	O2-07-03: Complement C3-deficiency preserves hippocampal synapses and neurons with aging and improves learning and memory compared to WT mice. , 2013, 9, P328-P328.		0
46	MER5101, a Novel A β ¹⁻¹⁵ :DT Conjugate Vaccine, Generates a Robust Anti-A β Antibody Response and Attenuates A β Pathology and Cognitive Deficits in APP ^{swe} /PS1 ^{E9} Transgenic Mice. <i>Journal of Neuroscience</i> , 2013, 33, 7027-7037.	3.6	50
47	Passive Immunization against Pyroglutamate-3 Amyloid- β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study. <i>Neurodegenerative Diseases</i> , 2012, 10, 265-270.	1.4	63
48	Galactic Cosmic Radiation Leads to Cognitive Impairment and Increased A β Plaque Accumulation in a Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2012, 7, e53275.	2.5	171
49	Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar A β by microglia. <i>Glia</i> , 2012, 60, 993-1003.	4.9	136
50	Can Alzheimer disease be prevented by amyloid- β immunotherapy?. <i>Nature Reviews Neurology</i> , 2010, 6, 108-119.	10.1	329
51	Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2010, 3, 1.	6.2	424
52	Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. <i>Progress in Brain Research</i> , 2009, 175, 83-93.	1.4	74
53	Amyloid- β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. <i>Nature Medicine</i> , 2008, 14, 837-842.	30.7	3,225
54	Complement C3 Deficiency Leads to Accelerated Amyloid β Plaque Deposition and Neurodegeneration and Modulation of the Microglia/Macrophage Phenotype in Amyloid Precursor Protein Transgenic Mice. <i>Journal of Neuroscience</i> , 2008, 28, 6333-6341.	3.6	274

#	ARTICLE	IF	CITATIONS
55	A beneficial role for IL-1 β in Alzheimer disease?. <i>Journal of Clinical Investigation</i> , 2007, 117, 1483-1485.	8.2	18
56	Characterization of A β ^{11-40/42} peptide deposition in Alzheimer's disease and young Down syndrome brains: implication of N-terminally truncated A β ² species in the pathogenesis of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2006, 112, 163-174.	7.7	87
57	Reduced β -Amyloid Production and Increased Inflammatory Responses in Presenilin Conditional Knock-out Mice. <i>Journal of Biological Chemistry</i> , 2004, 279, 46907-46914.	3.4	148
58	Evidence for peripheral clearance of cerebral A β ² protein following chronic, active A β ² immunization in PSAPP mice. <i>Neurobiology of Disease</i> , 2003, 14, 10-18.	4.4	151
59	Intraneuronal A β ²⁴² accumulation in Down syndrome brain. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2002, 9, 88-102.	3.0	237
60	Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. <i>Neurobiology of Aging</i> , 2002, 23, 991-1000.	3.1	71
61	Intraneuronal A β ⁴² accumulation in Down syndrome brain. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2002, 9, 88-102.	3.0	109
62	Inflammatory Responses to Amyloidosis in a Transgenic Mouse Model of Alzheimer's Disease. <i>American Journal of Pathology</i> , 2001, 158, 1345-1354.	3.8	275
63	Temporal Accrual of Complement Proteins in Amyloid Plaques in Down's Syndrome with Alzheimer's Disease. <i>American Journal of Pathology</i> , 2000, 156, 489-499.	3.8	157
64	The E280A presenilin 1 Alzheimer mutation produces increased A β ²⁴² deposition and severe cerebellar pathology. <i>Nature Medicine</i> , 1996, 2, 1146-1150.	30.7	489
65	The Swedish mutation causes early-onset Alzheimer's disease by β -secretase cleavage within the secretory pathway. <i>Nature Medicine</i> , 1995, 1, 1291-1296.	30.7	529